US Patent

US10596278 — Stable, concentrated radionuclide complex solutions

Formulation · Assigned to Advanced Accelerator Applications Italy SRL · Expires 2038-07-25 · 12y remaining

Vulnerability score 42/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects a method for creating stable, concentrated solutions of radionuclide complexes suitable for use as a drug product.

USPTO Abstract

The present invention relates to radionuclide complex solutions of high concentration and of high chemical stability, that allows their use as drug product for diagnostic and/or therapeutic purposes. The stability of the drug product is achieved by at least one stabilizer against radiolytic degradation. The use of two stabilizers introduced during the manufacturing process at different stages was found to be of particular advantage.

Drugs covered by this patent

Patent Metadata

Patent number
US10596278
Jurisdiction
US
Classification
Formulation
Expires
2038-07-25
Drug substance claim
No
Drug product claim
Yes
Assignee
Advanced Accelerator Applications Italy SRL
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.